Receive our newsletter – data, insights and analysis delivered to you
July 8, 2009

GSK’s Cervarix Proves Effective Against Cervical Cancer in Trials

GlaxoSmithKline (GSK) has announced that efficacy trials for the cervical cancer vaccine Cervarix have shown that the drug is effective at protecting against cervical cancer-causing human papillomavirus (HPV)types, 16 and 18. The study,which involved 18,644 women, also showed that the vac

By cms admin

GlaxoSmithKline (GSK) has announced that efficacy trials for the cervical cancer vaccine Cervarix have shown that the drug is effective at protecting against cervical cancer-causing human papillomavirus (HPV)types, 16 and 18.

The study,which involved 18,644 women, also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types beyond 16 and 18.

GSK Biologicals head of global clinical R&D and chief medical officer Thomas Breuer said that for the first time the results show that this vaccine was effective against cervical pre-cancers associated with the five most common cancer-causing virus types.

“This is really good news for primary prevention of cervical cancer as it indicates the vaccine could offer women additional protection beyond what had at first been anticipated,” Breuer said.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU